70988 Federal Register / Vol. 71, No.
235 / Thursday, December 7, 2006 / Notices
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with State and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic classes of controlled
substances listed.
Dated: November 28, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–20739 Filed 12–6–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated July 10, 2006, and
published in the Federal Register on
July 26, 2006, (71 FR 42418), Polaroid
Corporation, 1265 Main Street, Building
W6, Waltham, Massachusetts 02454,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of 2,5–
Dimethoxyamphetamine (7396), a basic
class of controlled substance listed in
schedule I.
The company plans to manufacture
the listed controlled substance in bulk
for conversion into a non-controlled
substance.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Polaroid Corporation to manufacture the
listed basic class of controlled substance
is consistent with the public interest at
this time. DEA has investigated Polaroid
Corporation to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with State and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
VerDate Aug<31>2005 17:29 Dec 06, 2006 Jkt 211001
Dated: November 28, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–20688 Filed 12–6–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By Notice dated August 15, 2006 and
published in the Federal Register on
August 22, 2006 (71 FR 48947),
Research Triangle Institute, Kenneth H.
Davis Jr., Hermann Building East
Institute Drive, P.O. Box 12194,
Research Triangle Park, North Carolina
27709, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as an importer of
Cocaine (9041), a basic class of
controlled substance listed in schedule
II.
The company plans to import small
quantities of the listed controlled
substance for the National Institute on
Drug Abuse and other clients.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Research Triangle Institute to import the
basic class of controlled substance is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971, at
this time. DEA has investigated
Research Triangle Institute to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
Dated: November 28, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–20746 Filed 12–6–06; 8:45 am]
BILLING CODE 4410–09–P
PO 00000 Frm 00043 Fmt 4703 Sfmt 4703 E:\FR\FM\07DEN1.SGM
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on September 21,
2006, Rhodes Technologies, 498
Washington Street, Coventry, Rhode
Island 02816, made application by letter
to the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of Oxymorphone (9652), a
basic class of controlled substance listed
in schedule II.
The company plans to manufacture
the listed controlled substance in bulk
for conversion and sale to dosage form
manufacturers.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative/ODL; or
any being sent via express mail should
be sent to DEA Headquarters, Attention:
DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than February 5, 2007.
Dated: November 28, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–20691 Filed 12–6–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated July 25, 2006, and
published in the Federal Register on
July 31, 2006, (71 FR 43211–43212),
Roche Diagnostics Operations, Inc.,
Attn: Regulatory Compliance, 9115
Hague Road, Indianapolis, Indiana
46250, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in schedule
I and II:
07DEN1